Background: Relapse is a relatively sudden worsening of neurological status in multiple sclerosis patients. The aim of this paper is to describe the frequency and timing of the subsequent clinical remission, and factors linked to a possible lack of recovery. Methods: Two hundred and twenty-three relapses in 62 multiple sclerosis patients were examined retrospectively. Kurtzke’s Expanded Disability Status Scale (EDSS) scores were calculated every 3 months from 1 year before to 1 year after. Remission was defined as improvement vs. the EDSS as scored during the relapse. Recovery was defined as return to the EDSS as scored before the relapse. Results: The frequency of improvement was 78% at 3 months, 86% at 6, and lower in males (65 vs. 81%). The frequency of recovery was 55% at 3 months, 71% at 6. Kaplan-Meier curves showed stabilization after 6 months, with improvement in 90% of patients, 100% without further relapses. Relapses without recovery were only 30%; 15% excluding short-term relapses. Conclusions: Incomplete remissions do not appear to be linked to the evolution of the relapse, but to further relapses in the following months; in other words, to the short-term relapse rate.

Keywords:
Relapsing-remitting multiple sclerosis, Expanded Disability Status Scale, Timing of remissions
1.
Achitii, Grimaud J, Confavreux C: Histoire naturelle et facteurs pronostiques de la sclérose en plaques. Med Ther 2001;7:13–16.
2.
Confavreux C, Vukusic S, Moreau T, Adeleine P: Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430–1438.
3.
Confavreux C, Vukusic S, Adeleine P: Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126:770–782.
4.
Agence Nationale d’Accréditation et d’Eva-luation en Santé et Fédération Française de Neurologie: Conférence de consensus: La sclérose en plaques; Paris, Juin 2001.
5.
Goodkin DE: Interferon beta therapy for multiple sclerosis. Lancet 1998;352:1486–1487.
6.
Goodin DS, Frohman EM, Garmany G, et al: Disease modifying therapies in multiple sclerosis. Report of the therapeutics and technology assessment subcommittee of the American academy of neurology and the MS council for clinical practice guidelines. Washington, Paralyzed Veterans of America, 2002.
7.
Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, Ebers GC: The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133–146.
8.
Kurtzke JF: Rating neurological impairment in multiple sclerosis: an Expanded Disabil-ity Status Scale (EDSS). Neurology 1983;33:1444–1452.
9.
Kurtzke J: The disability status scale for multiple sclerosis: apologia pro DSS sua. Neurology 1989;39:291–302.
10.
Rio J, Nos C, Tintore M, Borras C, Galan I, Comabella M, Montalban X: Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon B: implications for clinical trials. Ann Neurol 2002;52:400–406.
11.
McDonald I, et al: Recommended diagnostic criteria for MS. Ann Neurol 2001;50:121–127.
12.
Rudick RA, Cutter G, Reingold S: The multiple sclerosis functional composite: a new clinical outcome measure for multiple sclerosis trials. Mult Scler 2002;5:359–365.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.